Efficacy and Safety of Plasma Exchange as an Adjunctive Therapy for Rapidly Progressive IgA Nephropathy and Henoch-Schönlein Purpura Nephritis: A Systematic Review
by
, , , , , and
Bryan Nguyen
1,
Chirag Acharya
1,
Supawit Tangpanithandee
2,†
,
Jing Miao
2,
Pajaree Krisanapan
2,3
,
Charat Thongprayoon
2,
Omar Amir
1,
Michael A. Mao
4,
Wisit Cheungpasitporn
2,*
and
Prakrati C. Acharya
1 1
Division of Nephrology, Texas Tech Health Sciences Center El Paso, El Paso, TX 79905, USA
2
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
3
Division of Nephrology, Department of Internal Medicine, Thammasat University, Pathum Thani 12120, Thailand
4
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA
*
Author to whom correspondence should be addressed.
†
Current address: Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, Thailand.
Int. J. Mol. Sci. 2023, 24(4), 3977; https://doi.org/10.3390/ijms24043977
Submission received: 11 January 2023
/
Revised: 9 February 2023
/
Accepted: 13 February 2023
/
Published: 16 February 2023
(This article belongs to the Special Issue Vasculitis)
Abstract
:Patients with IgA nephropathy (IgAN), including Henoch-Schönlein purpura nephritis (HSP), who present with rapidly progressive glomerulonephritis (RPGN) have a poor prognosis despite aggressive immunosuppressive therapy. The utility of plasmapheresis/plasma exchange (PLEX) for IgAN/HSP is not well established. This systematic review aims to assess the efficacy of PLEX for IgAN and HSP patients with RPGN. A literature search was conducted using MEDLINE, EMBASE, and through Cochrane Database from inception through September 2022. Studies that reported outcomes of PLEX in IgAN or HSP patients with RPGN were enrolled. The protocol for this systematic review is registered with PROSPERO (no. CRD42022356411). The researchers systematically reviewed 38 articles (29 case reports and 9 case series articles) with a total of 102 RPGN patients (64 (62.8%) had IgAN and 38 (37.2%) had HSP). The mean age was 25 years and 69% were males. There was no specific PLEX regimen utilized in these studies, but most patients received at least 3 PLEX sessions that were titrated based on the patient’s response/kidney recovery. The number of PLEX sessions ranged from 3 to 18, and patients additionally received steroids and immunosuppressive treatment (61.6% of patients received cyclophosphamide). Follow-up time ranged from 1 to 120 months, with the majority being followed for at least 2 months after PLEX. Among IgAN patients treated with PLEX, 42.1% (n = 27/64) achieved remission; 20.3% (n = 13/64) achieved complete remission (CR) and 18.7% (n = 12/64) partial remission (PR). 60.9% (n = 39/64) progressed to end-stage kidney disease (ESKD). Among HSP patients treated with PLEX, 76.3% (n = 29/38) achieved remission; of these, 68.4% (n = 26/38) achieved CR and 7.8% achieved (n = 3/38) PR. 23.6% (n = 9/38) progressed to ESKD. Among kidney transplant patients, 20% (n = 1/5) achieved remission and 80% (n = 4/5) progressed to ESKD. Adjunctive plasmapheresis/plasma exchange with immunosuppressive therapy showed benefits in some HSP patients with RPGN and possible benefits in IgAN patients with RPGN. Future prospective, multi-center, randomized clinical studies are needed to corroborate this systematic review’s findings.
1. Introduction
IgA Nephropathy (IgAN), characterized by mesangial accumulation of IgA in kidney biopsy, is the most common type of primary glomerular disease and remains a leading cause of end-stage kidney disease (ESKD) in the world with an estimated incidence of 2.5 per 100,000 persons worldwide [1,2,3,4,5]. The overall prevalence of kidney biopsy-proven IgAN ranges from 4 to 44%, depending on the biopsy criterion and patient descent; the strongest predilection is towards Southeast Asians [1,6,7]. Although synpharyngitic macroscopic hematuria is well recognized as a clinical hallmark of IgAN, the most common initial symptoms in adult patients are microscopic hematuria and/or proteinuria [4,6,8]. The pathophysiology of IgAN is currently considered to be from a multi-“hit” process influenced by genetic and environmental factors [6], resulting in the presence of IgG autoantibodies and galactose-deficient IgA1 circulating immune complexes that deposit in the kidney mesangium. This activates the alternative complement pathway, local inflammation, glomerulosclerosis, and tubulointerstitial fibrosis, resulting in the loss of kidney function [6]. The disease course of IgAN is variable but often slowly progressive; about 25% of cases progress to ESKD within 10 years and about 40% progress within 20 years [9]. The risk of ESKD progression is greater in patients of Southeast Asian descent and those with preexisting risk factors of hypertension, diabetes mellitus, and proteinuria than in patients with different backgrounds [10,11].
IgA vasculitis, also known as Henoch-Schönlein purpura (HSP), is a systemic vasculitis characterized by IgA immune complex deposition within the blood vessels of the affected tissue. HSP is the most prevalent form of vasculitis in children, presenting as rashes, joint pain, gastrointestinal symptoms, and kidney disease. It is usually self-limiting in children but more severe in adults. Kidney biopsy in HSP-associated IgA nephropathy is indistinguishable from that seen in IgAN [4,12,13]. Even though HSP results in greater organ involvement, the risk of ESKD in adults with HSP-associated IgAN is comparable to that of IgAN [14].
To date, the 2021 Kidney Disease Improving Global Outcomes (KDIGO) guidelines for glomerulonephritis recommends the use of angiotensin-converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARB) as first-line therapy for the management of all IgAN patients with hypertension or significant proteinuria. Immunosuppressants should be used only if patients remain at high risk for the progression of chronic kidney disease (CKD) despite maximal supportive care or in patients with rapidly progressive glomerulonephritis (RPGN), which is defined as a ≥50% decline in estimated glomerular filtration rate (eGFR) within 3 months. Treatment options to mitigate ESKD progression are still limited for IgAN with crescentic disease [2].
Plasmapheresis or plasma exchange (PLEX) is a therapeutic procedure involving the extracorporeal removal or exchange of blood plasma, which includes its components of antibodies and circulating antigen-antibody complexes [15,16]. PLEX has been beneficial in the treatment of crescentic glomerulonephritis or RPGN due to anti-glomerular basement membrane (GBM) antibody disease and ANCA-associated vasculitis (AAV) [17,18]. Since the pathophysiology of IgAN includes circulating immune complexes, the use of PLEX as adjunctive therapy for IgAN with RPGN could theoretically be advantageous. According to the American Society for Apheresis 2019 guidelines, the role of PLEX may be considered individually in the treatment of IgAN and HSP with rapidly progressive/crescentic (recommendation category III) disease. However, this recommendation is weak due to the lack of randomized/prospective data regarding PLEX use [19]. Thus, this systematic review aims to consolidate existing data and assess the efficacy and safety of PLEX for the treatment of IgAN and HSP-associated IgAN patients with RPGN.
2. Materials and Methods
2.1. Information Sources and Search Strategy
The protocol for this systematic review is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42022356411). A systematic literature search was conducted utilizing Ovid Medline, EMBASE, the Cochrane Central Register of Controlled Trials (CCTR), and the Cochrane Database of Systematic Reviews (CDSR) from inception through September 2022 to identify all original studies that investigated the use of PLEX for the treatment of IgAN or HSP with associated RPGN (with or without crescents). Both native and transplanted kidneys affected by IgAN were included. The systematic literature review was individually conducted by two investigators (P.K. and S.T.) using the search strategy as described in the online Supplementary Data. The search strategy included the terms “plasmapheresis or apheresis or plasma exchange” AND “IgA nephropathy or Henoch Schönlein purpura”. A manual search for additional potentially relevant studies using the references of the included articles was also performed. No language limitation was applied. Any differing decisions were resolved by mutual consensus. This study was conducted in agreement with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) Statement as described in the online Supplementary Data.
2.2. Selection Criteria
Eligible studies included case reports, case series, and cohort studies that evaluated the role of PLEX in the treatment of IgAN or HSP with associated RPGN (with or without crescents). Studies had to report the following outcomes: remissions, relapses, degree of proteinuria, and serum creatinine/estimated glomerular filtration rate. The exclusion criteria included studies that primarily reported other treatment outcomes. Inclusion was not restricted by study size. Remission was determined by the reduction of proteinuria based on each article. In general, complete remission (CR) was defined as proteinuria of less than 0.3 g per 24 h, and partial remission (PR) was defined as a reduction of proteinuria between 0.3 and 3.5 g per 24 h and a 50% reduction from baseline. The quality of each study was evaluated by the investigators using the validated methodological index for non-randomized studies (minors) quality score.
2.3. Data Abstraction
A structured data collection report was adopted to derive the following information from the included studies: first author’s name, publication year, country of reporting, demographic data, kidney biopsy features, treatment regimen for PLEX, other treatments given, native or transplanted kidney, the outcome of treatment, adverse effects encountered, and other accompanying disease which would affect the kidneys or would cause alveolar hemorrhage and thrombotic microangiopathy. To ensure precision, this data extraction process was independently performed by three investigators (B.N., P.A, and W.C.)
3. Results
After excluding duplications, the search strategy retrieved 1382 potentially relevant articles. After excluding 1275 articles based on the titles and abstracts not fulfilling the inclusion criteria (as described in Figure 1, 107 articles underwent full-length review. An additional 69 articles were excluded due to either a lack of outcome of interest or poor methodological quality. Consequently, 38 studies (29 case reports and 9 case series) with 102 patients were enrolled in the analysis. These 38 studies underwent an assessment of methodological quality utilizing the tool published by Murad et al. in 2018 [20]. The literature retrieval, review, and selection process are shown in Figure 1. The characteristics of all included studies are shown in Table 1 and Table 2. The assessment of methodological quality for each included study is shown in Supplementary Tables S1 and S2.
3.1. Effect of Plasmapheresis in Native Kidneys with IgA Nephropathy
Among patients with IgAN, nearly half of the patients (42.1%, n = 27/64) achieved remission; of those, 20.3% (n = 13/64) achieved CR and 18.7% (n = 12/64) achieved PR. The remainder (60.9%, n = 39/64) progressed to ESKD.
3.2. Effect of Plasmapheresis in Patients with HSP
Among patients with HSP, 76.3% (n = 29/38) achieved remission; of those, 68.4% (n = 26/38) achieved CR and 7.8% (n = 3/38) achieved PR. Only 23.6% (n = 9/38) of patients progressed to ESKD.
3.3. Effect of Plasmapheresis in Patients with Transplanted Kidneys with IgA Nephropathy
The analysis of the included studies found that only five patients were reported to receive PLEX for IgAN with RPGN in transplanted kidneys. Only one of these five kidney transplant recipients (20%) achieved remission, while the remaining four (80%) developed ESKD.
3.4. Alveolar Hemorrhage with IgA Nephropathy
Pulmonary renal syndrome with IgA nephropathy was reported in the included studies. Eleven out of the 84 included patients who were treated with PLEX for IgAN had an alveolar hemorrhage, and the majority of these (10/11) patients had improvement or resolution of pulmonary symptoms after treatment. Four of these patients had a concomitant glomerular disease with IgA nephropathy, including two patients with ANCA positivity, one with Anti GBM antibody positivity, and one with hemolytic uremic syndrome. The role of plasma exchange in pulmonary-renal syndromes for Anti GBM and ANCA vasculitis is well established, and PLEX has been successfully utilized in atypical HUS. Some of the included patients did have concomitant illness along with IgAN (as noted above in Table 1 and Table 2) but overall appeared to have a good response in terms of pulmonary symptoms.
3.5. Adverse Events of Plasmapheresis
Infectious complications (8 of 102 patients) were the most commonly reported adverse event. All patients who developed infectious complications were on immunosuppressants, including steroids, mycophenolate, and cyclophosphamide. These infectious complications included catheter-associated sepsis, septic shock, bacterial pneumonia, cytomegalovirus (CMV) viremia, pneumocystis (PJP) pneumonia, influenza A, herpes zoster, and Rothia bacteremia. There were also reports of volume overload and cardiac arrest attributed to hypocalcemia and anaphylaxis. One patient developed an itchy rash following FFP that resolved after treatment with steroids and chlorpheniramine. Another patient developed femoral vein thrombosis, and one patient had PLEX catheter dislodgment. Reported adverse events are summarized in Table 3.
4. Discussion
This systematic review demonstrates the potential role of PLEX in the treatment of rapidly progressive/crescentic IgAN and HSP. Plasmapheresis’s removal of immune complexes may have a role in the treatment of aggressive forms of IgA and HSP.
This comprehensive analysis demonstrated a larger benefit with PLEX on HSP compared to IgAN patients (76.3% vs. 42.1% of patients achieved remission, respectively). The underlying reason for this variance is unclear, but it could possibly be related to the underlying pathophysiological differences between these diseases [59]. This study also demonstrated significant heterogeneity in treatment regimens, but a common theme was that early initiation of PLEX was associated with improved renal outcomes. In the Gianviti et al. case series, the five patients who did not achieve remission (reduction of proteinuria to less than 3.5 g per 24 h) did not start PLEX until 2 or more months after the onset of symptoms [40]. In contrast, nine of the ten patients who achieved at least partial remission and had stable kidney function over a follow-up period of 24–72 months had initiated plasmapheresis treatment within 1 month of symptom onset. This relationship was redemonstrated in the Shenoy et al. case series where all patients that initiated PLEX within 2 weeks of symptom onset achieved remission, whereas the single patient who delayed treatment until 2 months after symptom onset ultimately developed ESKD and required a kidney transplant [41]. The findings of this review support the KDIGO 2021 clinical practice guidelines that suggest treating RPGN due to IgA vasculitis similarly to ANCA-associated vasculitis where PLEX is sometimes utilized [2].
IgAN with pulmonary manifestations is rare, but all patients that presented with alveolar hemorrhage in our systematic review had significant improvement or resolution of pulmonary symptoms following PLEX. Although kidney outcomes following PLEX in IgAN with RPGN were ambivalent, these results support the use of PLEX in treating severe extra-renal manifestations of IgAN. PLEX has also been shown to have excellent outcomes in treating extra-renal manifestations of ANCA-associated vasculitis, which highlights the potentially shared pathophysiology between these two diseases [19].
Infectious complications arose in nearly 10% of analyzed patients. While most of the patients were already at high risk of infection due to adjunctive immunosuppression, carefully weighing risks-benefits prior to the initiation of PLEX and monitoring for infection is recommended given the impact of PLEX on both the immune system and antibiotic pharmacokinetics [60].
Crescentic disease was seen in most patients included in this analysis, regardless of IgAN or HSP status. Crescent formation is thought to be related to complement activation; prior studies have highlighted a positive correlation between urinary C4d and the degree of crescent development [61]. A crescent score was added to the Oxford MEST for grading IgAN severity in 2016 after their working group identified an inverse correlation between the degree of crescentic disease and kidney outcome [62]. However, the 2021 KDIGO guidelines recommended that the presence of crescents should not dictate therapy unless there is a concomitant change in eGFR [2]. The analysis failed to demonstrate an association between the degree of crescentic disease and kidney outcomes. Further randomized controlled trials and prospective data are needed to clarify the clinical utility of MEST-C and PLEX.
To the authors’ knowledge, this is the first systematic review of the use of PLEX for rapidly progressive and/or crescentic IgA nephropathy. However, there are several limitations. First, the majority of the published studies are case reports and case series, which often limits data to evaluate long-term outcomes. The literature search for this systematic review did not reveal any published randomized clinical trials that evaluated PLEX in rapidly progressive and/or crescentic GN with IgA nephropathy. Second, the included studies were heterogeneous in terms of the onset of treatment, treatment regimen, patient inclusion, and duration of follow-up. Finally, despite a comprehensive review, only a few kidney transplant patients were included, so the findings of this study may not be generalized for transplant patients.
5. Conclusions
In summary, this systematic review supports the benefit of plasmapheresis in HSP with RPGN, and it suggests a possible benefit of plasmapheresis in IgAN with RPGN. Randomized controlled trials are needed to further establish the role of plasmapheresis in rapidly progressive IgA nephropathy.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24043977/s1.
Author Contributions
Conceptualization, B.N., C.A., S.T., J.M., P.K., C.T., O.A., M.A.M., W.C. and P.C.A.; Data curation, B.N., W.C. and P.C.A.; Formal analysis, B.N. and P.C.A.; Funding acquisition, J.M., W.C. and P.C.A.; Investigation, B.N., C.A., S.T., J.M., P.K., C.T., O.A., W.C. and P.C.A.; Methodology, B.N., S.T., P.K., C.T., O.A., M.A.M., W.C. and P.C.A.; Project administration, B.N., C.A., S.T., P.K., C.T., O.A., M.A.M., W.C. and P.C.A.; Resources, B.N., S.T., C.T., O.A., W.C. and P.C.A.; Software, P.K., W.C. and P.C.A.; Supervision, C.A., J.M., P.K., C.T., O.A., M.A.M., W.C. and P.C.A.; Validation, B.N., C.A., S.T., O.A., W.C. and P.C.A.; Visualization, S.T. and P.C.A.; Writing—original draft, B.N. and P.C.A.; Writing—review & editing, B.N., C.A., S.T., J.M., P.K., C.T., O.A., M.A.M., W.C. and P.C.A.. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding authors.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Davin, J.C.; Ten Berge, I.J.; Weening, J.J. What is the difference between IgA nephropathy and Henoch-Schonlein purpura nephritis? Kidney Int. 2001, 59, 823–834. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021, 100, S1–S276. [Google Scholar] [CrossRef] [PubMed]
- Li, P.K.; Ho, K.K.; Szeto, C.C.; Yu, L.; Lai, F.M. Prognostic indicators of IgA nephropathy in the Chinese--clinical and pathological perspectives. Nephrol. Dial. Transpl. 2002, 17, 64–69. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rajasekaran, A.; Julian, B.A.; Rizk, D.V. IgA Nephropathy: An Interesting Autoimmune Kidney Disease. Am. J. Med. Sci. 2021, 361, 176–194. [Google Scholar] [CrossRef] [PubMed]
- Pattrapornpisut, P.; Avila-Casado, C.; Reich, H.N. IgA Nephropathy: Core Curriculum 2021. Am. J. Kidney Dis. 2021, 78, 429–441. [Google Scholar] [CrossRef]
- Rodrigues, J.C.; Haas, M.; Reich, H.N. IgA Nephropathy. Clin. J. Am. Soc. Nephrol. 2017, 12, 677–686. [Google Scholar] [CrossRef] [Green Version]
- Floege, J. Primary glomerulonephritis: A review of important recent discoveries. Kidney Res. Clin. Pr. 2013, 32, 103–110. [Google Scholar] [CrossRef] [Green Version]
- Wyatt, R.J.; Julian, B.A. IgA nephropathy. N. Engl. J. Med. 2013, 368, 2402–2414. [Google Scholar] [CrossRef] [Green Version]
- Jarrick, S.; Lundberg, S.; Welander, A.; Carrero, J.J.; Hoijer, J.; Bottai, M.; Ludvigsson, J.F. Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study. J. Am. Soc. Nephrol. 2019, 30, 866–876. [Google Scholar] [CrossRef]
- Barbour, S.J.; Cattran, D.C.; Kim, S.J.; Levin, A.; Wald, R.; Hladunewich, M.A.; Reich, H.N. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int. 2013, 84, 1017–1024. [Google Scholar] [CrossRef] [Green Version]
- Knoop, T.; Vikse, B.E.; Svarstad, E.; Leh, S.; Reisaeter, A.V.; Bjorneklett, R. Mortality in patients with IgA nephropathy. Am. J. Kidney Dis. 2013, 62, 883–890. [Google Scholar] [CrossRef] [PubMed]
- Hetland, L.E.; Susrud, K.S.; Lindahl, K.H.; Bygum, A. Henoch-Schonlein Purpura: A Literature Review. Acta Derm. Venereol. 2017, 97, 1160–1166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leung, J.C.; Tang, S.C.; Chan, D.T.; Lui, S.L.; Lai, K.N. Increased sialylation of polymeric lambda-IgA1 in patients with IgA nephropathy. J. Clin. Lab. Anal. 2002, 16, 11–19. [Google Scholar] [CrossRef] [PubMed]
- Coppo, R.; Mazzucco, G.; Cagnoli, L.; Lupo, A.; Schena, F.P. Long-term prognosis of Henoch-Schönlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schönlein purpura. Nephrol. Dial. Transpl. 1997, 12, 2277–2283. [Google Scholar] [CrossRef] [PubMed]
- Miao, J.; Krisanapan, P.; Tangpanithandee, S.; Thongprayoon, C.; Mao, M.A.; Cheungpasitporn, W. Efficacy of extracorporeal plasma therapy for adult native kidney patients with Primary FSGS: A Systematic review. Ren. Fail. 2023, 45, 2176694. [Google Scholar] [CrossRef]
- Sergent, S.R.; Ashurst, J.V. Plasmapheresis. In StatPearls; StatPearls Publishing: Petersburg, FL, USA, 2022. [Google Scholar]
- Jayne, D.R.; Gaskin, G.; Rasmussen, N.; Abramowicz, D.; Ferrario, F.; Guillevin, L.; Mirapeix, E.; Savage, C.O.; Sinico, R.A.; Stegeman, C.A.; et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 2007, 18, 2180–2188. [Google Scholar] [CrossRef] [Green Version]
- Levy, J.B.; Turner, A.N.; Rees, A.J.; Pusey, C.D. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann. Intern. Med. 2001, 134, 1033–1042. [Google Scholar] [CrossRef]
- Padmanabhan, A.; Connelly-Smith, L.; Aqui, N.; Balogun, R.A.; Klingel, R.; Meyer, E.; Pham, H.P.; Schneiderman, J.; Witt, V.; Wu, Y.; et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J. Clin. Apher. 2019, 34, 171–354. [Google Scholar] [CrossRef]
- Murad, M.H.; Sultan, S.; Haffar, S.; Bazerbachi, F. Methodological quality and synthesis of case series and case reports. BMJ Evid. Based Med. 2018, 23, 60–63. [Google Scholar] [CrossRef] [Green Version]
- Coppo, R.; Basolo, B.; Giachino, O.; Roccatello, D.; Lajolo, D.; Mazzucco, G.; Amore, A.; Piccoli, G. Plasmapheresis in a patient with rapidly progressive idiopathic IgA nephropathy: Removal of IgA-containing circulating immune complexes and clinical recovery. Nephron 1985, 40, 488–490. [Google Scholar] [CrossRef]
- Díaz-Tejeiro, R.; Maduell, F.; Diez, J.; Esparza, N.; Errasti, P.; Purroy, A.; Pardo, J. Loss of renal graft due to recurrent IgA nephropathy with rapidly progressive course: An unusual clinical evolution. Nephron 1990, 54, 341–343. [Google Scholar] [CrossRef]
- Streather, C.P.; Scoble, J.E. Recurrent IgA nephropathy in a renal allograft presenting as crescentic glomerulonephritis. Nephron 1994, 66, 113–114. [Google Scholar] [CrossRef] [PubMed]
- Afessa, B.; Cowart, R.G.; Koenig, S.M. Alveolar hemorrhage in IgA nephropathy treated with plasmapheresis. South. Med. J. 1997, 90, 237–239. [Google Scholar] [CrossRef] [PubMed]
- McGregor, D.; Lynn, K.L.; Robson, R. Rapidly progressive IgA nephropathy with anti-myeloperoxidase antibodies responding to immunosuppression. Clin. Nephrol. 1998, 50, 64. [Google Scholar] [PubMed]
- Chen, T.C.; Chung, F.R.; Lee, C.H.; Huang, S.C.; Chen, J.B.; Hsu, K.T. Successful treatment of crescentic glomerulonephritis associated with adult-onset Henoch-Schoenlein purpura by double-filtration plasmapheresis. Clin. Nephrol. 2004, 61, 213–216. [Google Scholar] [CrossRef]
- Rech, J.; Fuchs, F.; Kallert, S.; Hueber, A.J.; Requadt, C.; Manger, B.; Kalden, J.R.; Amann, K.; Strauss, R.; Schulze-Koops, H. Plasmapheresis therapy in an elderly patient with rapidly progressive Henoch-Schonlein purpura with disseminated organ involvement. Clin. Rheumatol. 2007, 26, 112–114. [Google Scholar] [CrossRef]
- Fujinaga, S.; Ohtomo, Y.; Umino, D.; Mochizuki, H.; Murakami, H.; Shimizu, T.; Yamashiro, Y.; Kaneko, K. Plasma exchange combined with immunosuppressive treatment in a child with rapidly progressive IgA nephropathy. Pediatr. Nephrol. 2007, 22, 899–902. [Google Scholar] [CrossRef]
- Anantham, D.C.K.; Chuah, K.L.; Vathsala, A.; Eng, P. Pulmonary Capillaritis in IgA Nephropathy. South. Med. J. 2007, 100, 605–607. [Google Scholar] [CrossRef]
- Wang, A.; Wang, Y.; Wang, G.; Zhou, Z.; Xun, Z.; Tan, X. Mesangial IgA deposits indicate pathogenesis of anti-glomerular basement membrane disease. Mol. Med. Rep. 2012, 5, 1212–1214. [Google Scholar] [CrossRef] [Green Version]
- Pipili, C.; Pantelias, K.; Papaioannou, N.; Paraskevakou, H.; Grapsa, E. Hemolytic-uremic syndrome, malignant hypertension and IgA nephropathy: Successful treatment with plasma exchange therapy. Transfus. Apher. Sci. 2012, 47, 155–158. [Google Scholar] [CrossRef]
- Herzog, A.L.; Wanner, C.; Amann, K.; Lopau, K. First Treatment of Relapsing Rapidly Progressive IgA Nephropathy With Eculizumab After Living Kidney Donation: A Case Report. Transpl. Proc. 2017, 49, 1574–1577. [Google Scholar] [CrossRef] [PubMed]
- Otsuka, Y.; Takeda, A.; Horike, K.; Inaguma, D.; Goto, N.; Watarai, Y.; Morozumi, K. Early recurrence of active IgA nephropathy after kidney transplantation. Nephrology 2014, 19 (Suppl. 3i), 45–48. [Google Scholar] [CrossRef] [PubMed]
- Yim, D.K.; Lee, S.T.; Cho, H. Plasmaphresis therapy for pulmonary hemorrhage in a pediatric patient with IgA nephropathy. Korean J. Pediatr. 2015, 58, 402–405. [Google Scholar] [CrossRef] [Green Version]
- Hamilton, P.; Ogundare, O.; Raza, A.; Ponnusamy, A.; Gorton, J.; Alachkar, H.; Choudhury, J.; Barratt, J.; Kalra, P.A. Long-Term Therapeutic Plasma Exchange to Prevent End-Stage Kidney Disease in Adult Severe Resistant Henoch-Schonlein Purpura Nephritis. Case Rep. Nephrol. 2015, 2015, 269895. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ring, T.; Pedersen, B.B.; Salkus, G.; Goodship, T.H. Use of eculizumab in crescentic IgA nephropathy: Proof of principle and conundrum? Clin. Kidney J. 2015, 8, 489–491. [Google Scholar] [CrossRef] [Green Version]
- Doddi, P.; Gowda, K.; Ramachandran, R.; Nada, R.; Kumar, V.; Rathi, M.; Kohli, H.S.; Gupta, K.L. Plasma exchange in Immunoglobulin A nephropathy with thrombotic microangiopathy and acute cortical necrosis. Indian J. Nephrol. 2016, 26, 42–44. [Google Scholar] [CrossRef]
- Pannu, K.M.M.; McMohan, L. Plasma exchange-resistant atypical hemolytic uremic syndrome treated with eculizumab in a patient with background IgA disease. Nephrology 2016, 21, 268. [Google Scholar]
- Nissaisorakarn, P.; D’Agati, V.; Anis, K.; Jim, B. ANCA and IgA glomerulonephritis all in one: Prognosis and complications. BMJ Case Rep. 2017, 2017, bcr2017222080. [Google Scholar] [CrossRef]
- Soltanpour, K.C.T.; Shanley, P.F.; Khanna, A. A Case of Concurrent Catastrophic Antiphospholipid Syndrome and IGA Nephropathy. In Proceedings of the ASN Kidney Week 2017, New Orleans, LA, USA, 31 October–5 November 2017; American Society of Nephrology: Washington, DC, USA; p. 1127. [Google Scholar]
- Belmar Vega, L.; Fernandez-Diaz, C.; Palmou Fontana, N.; Rodrigo Calabia, E.; Martin Penagos, L.; Arias Rodriguez, M.; Fernandez Fresnedo, G. Pulmonary hemorrhage in a patient with IgA nefropathy. Nefrologia 2017, 37, 347–349. [Google Scholar] [CrossRef]
- Surmeli-Doven, S.; Delibas, A.; Gurses, I.; Kayacan, U.R.; Coskun-Yilmaz, B.; Esen, K.; Korkmaz, E.; Ozaltin, F. Hemolytic uremic syndrome and IgA nephropathy in a child: Coincidence or not? Turk J. Pediatr. 2018, 60, 81–85. [Google Scholar] [CrossRef]
- Krishnaswamy, S.; Rajiv, A.; Kumar, S. Pleomorphic presentations of IgA nephropathy-postrenal transplantation. Indian J. Transplant. 2018, 12, 219–223. [Google Scholar] [CrossRef]
- Gani, I.; Kleven, D.; Mulloy, L. Crescentic IgA nephropathy along with simultaneous cellular and antibody-mediated rejection in a kidney transplant leading to rapid allograft failure. Clin. Case Rep. 2019, 7, 1773–1776. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kojima, T.; Hirose, G.; Komatsu, S.; Oshima, T.; Sugisaki, K.; Tomiyasu, T.; Yoshikawa, N.; Yamada, M.; Oda, T. Development of anti-glomerular basement membrane glomerulonephritis during the course of IgA nephropathy: A case report. BMC Nephrol. 2019, 20, 25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Longano, A. Concurrent anti-GBM disease and IgA glomerulonephritis. Pathology 2019, 51, 336–338. [Google Scholar] [CrossRef]
- Bhuwania, P.; Veerappan, I.; Sethuraman, R. A Rare Case of Type 4 Rapidly Progressive Glomerulonephritis (Atypical) with Mesangial IgA Deposits: A Case Report. Indian J. Nephrol. 2021, 31, 488–491. [Google Scholar] [CrossRef]
- Apaydin, H.; Güven, S.C.; Doğan, I.; Çolak, A.; Erten, Ş. ANCA- positive IgA nephropathy presented as alveolar hemorrhage in a COVID-19 patient. Ann. Clin. Anal. Med. 2021, 12, 236–240. [Google Scholar] [CrossRef]
- Zhang, M.; Yang, D.; Wang, W.; Zhao, F.; Zhang, X.; Li, X. Pneumocystis pneumonia secondary to intensive immunosuppression treatment for anti-GBM disease complicated with IgA nephropathy: A case report and literature review. Medicine 2021, 100, e27728. [Google Scholar] [CrossRef]
- Lai, K.N.; Lai, F.M.; Leung, A.C.; Ho, C.P.; Vallance-Owen, J. Plasma exchange in patients with rapidly progressive idiopathic IgA nephropathy: A report of two cases and review of literature. Am. J. Kidney Dis. 1987, 10, 66–70. [Google Scholar] [CrossRef]
- Nicholls, K.; Becker, G.; Walker, R.; Wright, C.; Kincaid-Smith, P. Plasma exchange in progressive IgA nephropathy. J. Clin. Apher. 1990, 5, 128–132. [Google Scholar] [CrossRef]
- Roccatello, D.F.M.; Coppo, R.; Giraudo, G.; Quattrocchio, G.; Piccoli, G. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy. Nephrol. Dial. Transplant. 1995, 10, 2054–2059. [Google Scholar]
- Gianviti, A.T.R.; Barratt, T.M.; Lythgoe, M.F.; Dillon, M.J. Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis. Arch. Dis. Child. 1996, 75, 186–190. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shenoy, M.; Ognjanovic, M.V.; Coulthard, M.G. Treating severe Henoch-Schonlein and IgA nephritis with plasmapheresis alone. Pediatr. Nephrol. 2007, 22, 1167–1171. [Google Scholar] [CrossRef] [PubMed]
- Wright, E.; Dillon, M.J.; Tullus, K. Childhood vasculitis and plasma exchange. Eur. J. Pediatr. 2007, 166, 145–151. [Google Scholar] [CrossRef]
- Xie, X.; Lv, J.; Shi, S.; Zhu, L.; Liu, L.; Chen, M.; Wang, Y.; Cui, Z.; Wang, X.; Liu, L.; et al. Plasma Exchange as an Adjunctive Therapy for Crescentic IgA Nephropathy. Am. J. Nephrol. 2016, 44, 141–149. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chambers, M.M.B.; Hall, F.; Rabetoy, G. Plasmapheresis for Crescentic IgA Nephropathy: A Report of Two Cases and Review of the Literature. J. Clin. Apher. 1999, 14, 185–187. [Google Scholar] [CrossRef]
- Rajagopala, S.P.S.; Ajmera, J.S.; Ganesh, R.N.; Katrevula, A. Diffuse alveolar hemorrhage in IgA nephropathy: Case series and systematic review of the literature. Int. J. Rheum. Dis. 2017, 20, 109–121. [Google Scholar] [CrossRef] [PubMed]
- Guo, H.X.; Zhang, J.J.; Shi, P.P.; Fu, S.Q.; Zhang, L.G.; Wang, M.; Lu, F.X. A clinico-pathological comparison between Henoch-Schonlein purpura nephritis and IgA nephropathy in children. Zhongguo Dang Dai Er Ke Za Zhi 2012, 14, 506–509. [Google Scholar]
- Krzych, L.J.; Czok, M.; Putowski, Z. Is Antimicrobial Treatment Effective During Therapeutic Plasma Exchange? Investigating the Role of Possible Interactions. Pharmaceutics 2020, 12, 395. [Google Scholar] [CrossRef]
- Wang, Z.; Xie, X.; Li, J.; Zhang, X.; He, J.; Wang, M.; Lv, J.; Zhang, H. Complement Activation Is Associated With Crescents in IgA Nephropathy. Front. Immunol. 2021, 12, 676919. [Google Scholar] [CrossRef]
- Trimarchi, H.; Barratt, J.; Cattran, D.C.; Cook, H.T.; Coppo, R.; Haas, M.; Liu, Z.H.; Roberts, I.S.; Yuzawa, Y.; Zhang, H.; et al. Oxford Classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017, 91, 1014–1021. [Google Scholar] [CrossRef] [Green Version]
Figure 1.
Literature review process.
Table 1.
Characteristics of included case reports.
| Author | Year | Type of Study | n | Country | Age | Sex | HSP | Other Disease | Alveolar Hemorrhage | Crescents | Kidney Transplant | Plasma Exchange Regimen | Additional Treatment | Outcome | Adverse Event | Thrombotic Micro-angiopathy | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Coppo [21] | 1985 | Case Report | 1 | Italy | 54 | M | - | - | - | 20% gloms | - | 13 cycles total: 1 session every other day for 3 weeks then weekly sessions for 4 weeks | Steroids Cytoxan | Complete remission Cr clearance improved from 30 mL/min to 120 mL/min Proteinuria 3 g/day to 0.2 g/day at 6-month follow-up | - | - |
| 2 | Tejeiro [22] | 1990 | Case Report | 1 | Spain | 54 | M | - | - | - | +60% gloms | + | 18 cycles total 22 L removed | Steroids Cytoxan | Not reported | Failed transplant and progressed to ESKD | - |
| 3 | Streather [23] | 1994 | Case Report | 1 | UK | 43 | M | - | - | - | +40% gloms | + | 3 sessions with 3 L and 4.5% albumin | Steroids | Continued improvement in Cr | - | - |
| 4 | Affessa [24] | 1997 | Case Report | 1 | USA | 66 | M | - | - | + | + | - | 3× week for 3 weeks | Steroids | Cr 6.9 to 2.8 | Catheter dislodged | - |
| 5 | McGregor [25] | 1998 | Case Report | 1 | New Zealand | 14 | M | - | P-ANCA (MPO) | + | +90% gloms | - | 10 × 2 L exchanges over 3 weeks | Steroids Cytoxan | Cr normal Proteinuria persisted No further pulmonary hemorrhage | - | - |
| 6 | Chen [26] | 2004 | Case Report | 1 | Taiwan | 33 | M | + | - | - | + | - | 9 sessions of double filtration plasmapheresis | Steroids Cytoxan | S Cr from 11.4 to 3.1 | - | - |
| 7 | Rech [27] | 2005 | Case Report | 1 | Germany | 57 | M | + | - | - | - | - | 3 days first week, 2 days second week, 40 mL/kg with FFP | Steroids Cytoxan | HD until “normal serum creatinine” and resolution of proteinuria at 1 year | - | - |
| 8 | Fujinaga [28] | 2006 | Case Report | 1 | Japan | 5 | M | - | - | - | +80% gloms | - | 5 sessions alternating days 50 mL/kg | Steroids Mizoribine | HD discontinued 3 weeks after PLEX | - | - |
| 9 | Anantham [29] | 2007 | Case Report | 1 | Singapore | 20 | M | - | ESKD due to IgAN | + | + | - | Unclear | Cytoxan Steroids | Improvement in pulmonary hemorrhage, ESKD | - | - |
| 10 | Wang [30] | 2011 | Case Report | 1 | China | 31 | F | - | - | - | +14/17 gloms | - | 10 sessions | Steroids Cytoxan | Only mentioned Cr 3.75 after 1 mo therapy | - | - |
| 11 | Pipilli [31] | 2012 | Case Report | 1 | Greece | 35 | M | - | - | - | + | - | 17 sessions | Steroid | Cr from 7 to 2.5 | - | + |
| 12 | Herzog [32] | 2014 | Case Report | 1 | Germany | 28 | M | - | - | - | +7/12 gloms | - | 3 sessions 40 mL/kg | Steroids | ESKD | - | - |
| 13 | Otsuka [33] | 2014 | Case Report | 1 | Japan | 23 | M | - | - | - | - | + 19 days s/p | Double Filtration plasmapheresis | Steroids | Worsening Cr and proteinuria | CMV viremia | - |
| 14 | Yim [34] | 2014 | Case Report | 1 | Korea | 14 | M | - | - | + | +21/45 gloms | - | Daily plasmapheresis; weekly for 3 months | PD Steroids Cytoxan | Pulmonary symptoms resolved but progressed to ESKD | - | + |
| 15 | Hamilton [35] | 2015 | Case Report | 1 | UK | 27 | M | + | - | - | +20% gloms | - | 108 total sessions over 3 years; 2 weeks of daily sessions followed by empiric sessions every 1–2 weeks | Steroids Cytoxan Ritixumab IVIg | Gradual decline in renal function with ESKD at 3 years. Received live renal transplant at 3.5 years with stable Cr of 1.69 | - | - |
| 16 | Ring [36] | 2015 | Case Report | 1 | UK | 16 | M | + | - | - | +6/14 gloms | - | 5 Plasma exchange with 40 mL/kg | Steroids Cytoxan Eculizumab | Not mentioned | No improvement after PLAEX but after Eculizumab, then progressed to ESKD after 2 years | - |
| 17 | Doddi [37] | 2016 | Case Report | 1 | India | 25 | F | - | HUS | - | - | - | 5 sessions alternate day, 40 mL/kg | - | Cr normal in 3 months | - | + |
| 18 | Pannu [38] | 2016 | Case Report | 1 | USA | 25 | M | - | HUS | + | NR | - | PLEX >3 sessions | Eculizumab | Dialysis dependent | - | + |
| 19 | Nissaisorakarn [39] | 2017 | Case Report | 1 | USA | 75 | F | - | ANCA | - | +6/13 gloms | - | 7 sessions every other day | Steroids Cytoxan | ESKD | Influenza A, Herpes Zoster, Rothia bacteremia | - |
| 20 | Soltanpour [40] | 2017 | Case Report | 1 | USA | 42 | M | - | APLS | - | NR | - | PLEX | Steroids | Not reported | Cr improved to 1.9 from 4.5 | + |
| 21 | Vega [41] | 2017 | Case Report | 1 | Spain | 69 | M | + | - | + | - | - | 6 | Steroids IVIG 3 mo | Cr 2.1 to 1.2 (unknown time) | - | - |
| 22 | Sürmeli-Döven [42] | 2018 | Case Report | 1 | Turkey | 1.5 | M | - | HUS | - | - | - | 5 sessions with 1-day intervals | Steroids | Dialysis to Cr 0.52 | - | + |
| 23 | Rajiv [43] | 2018 | Case Report | 1 | India | 26 | M | - | - | - | + | + | 6 sessions | Steroids IVIG Cytoxan | ESKD | - | - |
| 24 | Gani [44] | 2019 | Case Report | 1 | USA | 36 | M | - | Humoral and cell-mediated rejection | - | + | + | 7 sessions | Steroids Thymoglobulin | ESKD | - | - |
| 25 | Kojima [45] | 2019 | Case Report | 1 | Japan | 66 | F | - | Anti GBM | + | +1/18 glom | - | 8 sessions | Steroids | ESKD | - | - |
| 26 | Longano [46] | 2019 | Case Report | 1 | Australia | 22 | M | - | Anti GBM | + | +2/11 gloms | - | 21 sessions | Steroids Cytoxan | Cr remained normal | - | - |
| 27 | Bhuwania [47] | 2020 | Case Report | 1 | India | 58 | F | - | ANCA Anti GBM | - | +M1S1C1 | - | 5 sessions | Steroids Cytoxan (CYCLOPS) | Cr 3.5 to 1.4 at 6 m | - | - |
| 28 | Apaydin [48] | 2021 | Case Report | 1 | Turkey | 18 | M | - | COVID PR3ANCA | + | + | - | Daily sessions for 7 days | Steroids IVIg | Cr from 0.96 to 1.15 | - | - |
| 29 | Zhang [49] | 2021 | Case Report | 1 | China | 41 | F | - | Anti GBM | - | + | - | 6 sessions | Steroids Rituximab, HD × 3 IVIG 12 mo Tacrolimus | HD discontinued, Cr 2.79–1.517 at 28 wk | PCP | - |
Abbreviations: ANCA, Antineutrophil cytoplasmic antibody; Anti-GBM, Anti glomerular basement membrane disease; APLS, anti-phospholipid disease; Cr, creatinine; ESKD, end-stage kidney disease; Gloms, glomeruli; HD, hemodialysis; HUS, hemolytic uremic syndrome; IgAN, IgA nephropathy; PLEX, plasma exchange therapy.
Table 2.
Characteristic of included case series.
| Author | Year | Country /Patient no. | Study Population | Age (Yrs) | Other Disease | Initial Kidney Function | Kidney Biopsy | Treatment Regimen | Additional Treatment | Outcome | Adverse Events | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lai [50] | 1987 | UK | 2 patients; 2F | 21–24 | IgAN HTN | Each patient had a different plasma exchange regimen. | Steroids AZA | Both patients saw temporary improvement in serum creatinine following plasma exchange therapy but kidney function gradually deteriorated despite therapy. | Leukopenia | ||
| 1 | F | 24 | IgAN HTN | sCr 8.22 mg/dL (727 µmol/L) | 20 glomeruli; 13 sclerosed and 7 with fibro-cellular crescents | 4 courses consisting of 4 plasma exchanges on alternating days separated by 2–3 months. The first plasma exchange occurred 2 weeks after symptom onset. | Steroids AZA | sCr: 8.14 mg/dL (720 µmol/L) at 3 weeks 4.58 mg/dL (405 µmol/L) at 1 month 9.61 mg/dL (850 µmol/L) at 4 months 5.76 mg/dL (510 µmol/L) at 6 months 10.29 mg/dL (910 µmol/L) at 7 months 5.66 mg/dL (500 µmol/L) at 10 months 11.31 mg/dL (1000 µmol/L) at 12 months ESKD on HD at 15 month follow up | Leukopenia from AZA | |||
| 2 | F | 21 | IgAN HTN | sCr 8.22 mg/dL (425 µmol/L) | 15 glomeruli; 5 sclerosed 10 with fibro-cellular crescents | 6 plasma exchanges on alternating days 2 months after symptom onset. | Steroids AZA | sCr: 5.09 mg/dL (450 µmol/L) at 2 months 9.61 mg/dL (850 µmol/L) at 3 months 5.77 mg/dL (510 µmol/L) at 5 months 5.66 mg/dL (500 µmol/L) at 7 months 6.78 mg/dL (600 µmol/L) at 9 months 7.35 mg/dL (650 µmol/L) at 12 months Progressive deterioration thereafter | None | |||
| 2 | Nicholls [51] | 1990 | AUS | 14 patients; 11M and 3F | 17–58 | IgAN HTN | All patients had crescents on biopsy with mean of 40% crescents in non-sclerosed glomeruli (median 34%; range 7–80%) No individualized biopsy results were provided | 4 plasma exchanges on consecutive days followed by 3 plasma exchanges weekly for 2 weeks, then weekly plasma exchange until 3 months total duration. | Dipyridamole Cytoxan | 7 patients experienced fall in sCr during treatment protocol while the renal function of the rest progressively deteriorated during the study. However, all patients ultimately experienced decline in renal function after completion of treatment with all but 4 patients requiring HD. The authors did not provide final outcomes for each individual patient. The 7 patients who had improved with plasma exchange experienced a notably slower rate of decline in renal function compared to the other patients. | Acute Tubular Necrosis in 1 patient | |
| 1 | M | 18 | IgAN HTN | sCr 1.81 mg/dL (160 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 2.14 mg/dL (190 µmol/L) at 3 months 2.04 mg/dL (180 µmol/L) at 6 months 2.26 mg/dL (200 µmol/L) at 9 months | ||||||
| 2 | M | 23 | IgAN HTN | sCr 3.73 mg/dL (330 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 4.41 mg/dL (390 µmol/L) at 3 months 4.18 mg/dL (370 µmol/L) at 6 months 4.41 mg/dL (440 µmol/L) at 9 months | ||||||
| 3 | M | 30 | IgAN HTN | sCr 3.95 mg/dL (350 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 6.11 mg/dL (540 µmol/L) at 3 months 5.66 mg/dL (500 µmol/L) at 6 months 7.58 mg/dL (670 µmol/L) at 9 months | ||||||
| 4 | M | 26 | IgAN HTN | sCr 2.26 mg/dL (200 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 2.83 mg/dL (250 µmol/L) at 3 months 1.92 mg/dL (170 µmol/L) at 6 months 2.49 mg/dL (220 µmol/L) at 9 months | ||||||
| 5 | F | 40 | IgAN HTN | sCr 2.83 mg/dL (250 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 10.63 mg/dL (940 µmol/L) at 3 months 7.58 mg/dL (670 µmol/L) at 6 months 20.36 mg/dL (1800 µmol/L) at 9 months | ||||||
| 6 | F | 50 | IgAN HTN | sCr 1.70 mg/dL (150 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 2.37 mg/dL (210 µmol/L) at 3 months 2.03 mg/dL (180 µmol/L) at 6 months 2.26 mg/dL (200 µmol/L) at 9 months | ||||||
| 7 | M | 17 | IgAN HTN | sCr 6.33 mg/dL (560 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 14.37 mg/dL (1270 µmol/L) at 3 months 8.82 mg/dL (780 µmol/L) at 6 months 15.61 mg/dL (1380 µmol/L) at 9 months | ||||||
| 8 | M | 58 | IgAN HTN | sCr 4.75 mg/dL (420 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 5.43 mg/dL (480 µmol/L) at 3 months 5.77 mg/dL (510 µmol/L) at 6 months 7.47 mg/dL (660 µmol/L) at 9 months | ||||||
| 9 | F | 20 | IgAN HTN | sCr 4.52 mg/dL (400 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 5.32 mg/dL (470 µmol/L) at 3 months 8.71 mg/dL (770 µmol/L) at 6 months 12.10 mg/dL (1070 µmol/L) at 9 months | ||||||
| 10 | M | 50 | IgAN HTN | sCr 2.83 mg/dL (250 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 3.28 mg/dL (290 µmol/L) at 3 months 3.28 mg/dL (290 µmol/L) at 6 months 3.39 mg/dL (300 µmol/L) at 9 months | ||||||
| 11 | M | 22 | IgAN HTN | sCr 4.18 mg/dL (370 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 4.18 mg/dL (370 µmol/L) at 3 months 5.43 mg/dL (480 µmol/L) at 6 months 8.03 mg/dL (710 µmol/L) at 9 months | ||||||
| 12 | M | 43 | IgAN HTN | sCr 7.35 mg/dL (650 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 8.03 mg/dL (710 µmol/L) at 3 months 10.29 mg/dL (910 µmol/L) at 6 months 22.51 mg/dL (1990 µmol/L) at 9 months | ||||||
| 13 | M | 23 | IgAN HTN | sCr 3.96 mg/dL (350 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 4.41 mg/dL (390 µmol/L) at 3 months 5.54 mg/dL (490 µmol/L) at 6 months 9.95 mg/dL (880 µmol/L) at 9 months | ||||||
| 14 | M | 44 | IgAN HTN | sCr 2.37 mg/dL (210 µmol/L) | Plasma exchange was initiated 3 months after enrollment. | sCr: 8.48 mg/dL (750 µmol/L) at 3 months 3.39 mg/dL (300 µmol/L) at 6 months 4.41 mg/dL (390 µmol/L) at 9 months | Developed ATN thought to be related to intercurrent surgery during observation period, but it was withdrawn from analysis. | |||||
| 3 | Rocatello [52] | 1995 | Italy | 6 patients; 4M and 2F | 16–61 | IgAN | All patients except controls in IgAN group received 2 month treatment of 15 mg/kg IV methylprednisolone for 3 days followed by 8 weeks of oral prednisone (1 mg/kg for first 4 weeks and 0.75 mg/kg for last 4) Oral cyclophosphamide 2.5 mg/kg/day for 8 weeks. Plasma exchange (6 treatments in 2 weeks followed by weekly PLEX for at least 2 weeks). | Steroids Cytoxan | All patients saw improvement in serum creatinine and urine abnormalities, but 3 patients eventually developed ESKD at long-term follow up. No correlation between urine abnormalities, HTN, sCr, and histological features was found. No clinical or histological parameter was significantly different between patients in the treatment group. | Pneumonia in 1 patient | ||
| 1 | M | 16 | IgAN HTN | sCr 10.0 mg/dL (884 µmol/L) | 10 glomeruli 90% florid crescents and 10% fibrotic crescents 1+ interstitial fibrosis | 14 plasma exchanges in first month with 8 additional sessions by 2 month follow up. | Steroids Cytoxan | sCr: 2.4 mg/dL (212 µmol/L) at 2 months 2.19 mg/dL (194 µmol/L) at 6 months 5.9 mg/dL (522 µmol/L) at 16 months 7.43 mg/dL (657 µmol/L) at 24 months ESKD on HD at 36 month follow up Repeat biopsy at 16 months: 15 glomeruli 65% glomerular hyalinosis 15% florid crescents 1+ interstitial fibrosis 1+ vascular hyalinosis | - | |||
| 2 | M | 44 | IgAN HTN | sCr 1.2 mg/dL (106 µmol/L) | 12 glomeruli 15% glomerular hyalinosis 40% florid crescents 1+ interstitial infiltrates 1+ interstitial fibrosis 1+ vascular hyalinosis | 11 plasma exchanges in first month, no additional sessions. | Steroids Cytoxan | sCr: 1.1 mg/dL (97 µmol/L) at 2 months 1.49 mg/dL (132 µmol/L) at 6 months 1.49 mg/dL (132 µmol/L) at 24 months Repeat biopsy at 2 months: 26 glomeruli 30% glomerular hyalinosis 10% florid crescents 20% fibrotic crescents 1+ interstitial fibrosis 1+ vascular hyalinosis | - | |||
| 3 | F | 61 | IgAN HTN | sCr 7.19 mg/dL (636 µmol/L) | 20 glomeruli 5% glomerular hyalinosis 70% florid crescents 1+ interstitial infiltrates 1+ interstitial fibrosis 1+ vascular hyalinosis | 14 plasma exchanges in first month, no additional sessions. | Steroids Cytoxan | sCr: 3 mg/dL (265 µmol/L) at 2 months 5.1 mg/dL (451 µmol/L) at 6 months ESKD on HD at 1-year follow up Repeat biopsy at 2 months: 12 glomeruli 30% glomerular hyalinosis 50% florid crescents 1+ interstitial infiltrates 1+ interstitial fibrosis 1+ vascular hyalinosis | - | |||
| 4 | M | 39 | IgAN HTN | sCr 2.69 mg/dL (238 µmol/L) | 13 glomeruli 35% glomerular hyalinosis 50% florid crescents 1+ Interstitial fibrosis 1+ vascular hyalinosis | 10 plasma exchanges in first month with 5 additional sessions by 2 month follow up. | Steroids Cytoxan | sCr: 2.6 mg/dL (230 µmol/L) at 2 months 4.2 mg/dL (371 µmol/L) at 6 months ESKD on HD at 1-year follow up Repeat biopsy at 2 months: 14 glomeruli 30% glomerular hyalinosis 30% florid crescents 2+ interstitial fibrosis 2+ vascular hyalinosis | - | |||
| 5 | M | 55 | IgAN HTN | sCr 7.4 mg/dL (654 µmol/L) | 10 glomeruli 40% florid crescents 1+ interstitial infiltrates 2+ interstitial fibrosis | 10 plasma exchanges in first month, no additional sessions. | Steroids Cytoxan | sCr: 2.19 mg/dL (194 µmol/L) at 2 months 2.09 mg/dL (185 µmol/L) at 6 months 2.19 mg/dL (194 µmol/L) at 24 months 2.19 mg/dL (194 µmol/L) at 36 months ESKD on HD at 1-year follow up No repeat biopsy | - | |||
| 6 | F | 18 | IgAN | sCr 3.0 mg/dL (265 µmol/L) | 12 glomeruli 15% glomerular hyalinosis 80% florid crescents 1+ interstitial infiltrates 1+ interstitial fibrosis 1+ vascular hyalinosis | 18 plasma exchanges in first month with 5 additional sessions between the 2 and 6 months follow up. | Steroids Cytoxan | sCr: 1.49 mg/dL (1.32 µmol/L) at 2 months 2.3 mg/dL (2.03 µmol/L) at 6 months 1.59 mg/dL (1.41 µmol/L) at 24 months 4.2 mg/dL (371 µmol/L) at 120 months No repeat biopsy | - | |||
| 4 | Gianviti [53] | 1996 | UK | 14 patients; 10 M and 4F | 3.7–11.9 | HSP | 12/14 patients: 30–100% crescents | Children weighing below 15 kg underwent plasma filtration with a Gambro plasma filter and AK 10 blood monitor. Children above 15 kg underwent centrifugal plasma exchange with a Cobe Spectra Apheresis system. Total volume exchanged was twice the estimated plasma volume using Albumin and FFP as replacement fluids. | Cytoxan Steroids | All patients with improvement in serum Cr but 5 patients with ESKD at long-term follow up. Statistically significant improvement in kidney outcome if PLEX initiated within 1 month of disease onset. | Volume overload Cardiac arrest due to hypocalcemia Anaphylaxis | |
| 1 | F | 6.4 | HSP | sCr 1.24 mg/dL (110 µmol/L) | 60% crescents | 9 months from onset | Steroids Cytoxan | sCr 0.53 mg/dL (47 µmol/L) 2 months after PLEX ESKD at 2-year follow up | - | |||
| 2 | M | 9.0 | HSP | sCr 2.26 mg/dL (200 µmol/L) | 60% crescents | 4 months from onset | Steroids Cytoxan | sCr 1 mg/dL (88 µmol/L) 2 months after PLEX ESKD at 2-year follow up | - | |||
| 3 | M | 11.9 | HSP | sCr 0.97 mg/dL (86 µmol/L) | 80% crescents | 1 month from onset | Steroids Cytoxan | sCr 0.68 mg/dL (60 µmol/L) 2 months after PLEX sCr 0.9 mg/dL (80 µmol/L) at 2-year follow up | - | |||
| 4 | F | 9.5 | HSP | sCr 5.54 mg/dL (490 µmol/L) | 100% crescents | <1 month from onset | Steroids Cytoxan | sCr 1.36 mg/dL (120 µmol/L) 2 months after PLEX sCr 1.92 mg/dL (170 µmol/L) at 6-year follow up | - | |||
| 5 | M | 8.0 | HSP | sCr 8.03 mg/dL (710 µmol/L) | 80% crescents | 1 month from onset | Steroids Cytoxan HD | sCr 1.36 mg/dL (120 µmol/L) 2 months after PLEX sCr (76 µmol/L) at 1-year follow up | - | |||
| 6 | M | 5.1 | HSP | sCr 3.73 mg/dL (330 µmol/L) | Diffuse extra-capillary proliferation | <1 month from onset | Steroids Cytoxan HD | sCr (58 µmol/L) 2 months after PLEX sCr 0.86 mg/dL (58 µmol/L) at 2-year follow up | - | |||
| 7 | M | 10 | HSP | sCr 8.93 mg/dL (µmol/L) | Diffuse extra-capillary proliferation | 1 month from onset | Steroids Cytoxan HD | sCr (62 µmol/L) 2 months after PLEX (53 µmol/L) at 3-year follow up | - | |||
| 8 | M | 8.9 | HSP | sCr 1.27 mg/dL (112 µmol/L) | 50% crescents | 1 month from onset | Steroids Cytoxan | sCr 0.7 mg/dL (41 µmol/L) 2 months after PLEX sCr 0.68 mg/dL (60 µmol/L) at 2-year follow up | - | |||
| 9 | F | 11.5 | HSP | sCr 3.39 mg/dL (300 µmol/L) | 88% crescents | 1 month from onset | Steroids Cytoxan | sCr 0.98 mg/dL (87 µmol/L) 2 months after PLEX sCr 0.66 mg/dL (58 µmol/L) at 2-year follow up | - | |||
| 10 | M | 3.7 | HSP | sCr 1.4 mg/dL (124 µmol/L) | 30% crescents | 48 months from onset | Steroids Cytoxan | sCr 1.36 mg/dL (120 µmol/L) 2 months after PLEX ESKD at 7-year follow up | - | |||
| 11 | M | 5.6 | HSP | sCr 2.6 mg/dL (230 µmol/L) | 80% crescents | 1 month from onset | Steroids Cytoxan | sCr 0.68 mg/dL (60 µmol/L) 2 months after PLEX sCr 0.38 mg/dL (34 µmol/L) at 1.3-year follow up | - | |||
| 12 | F | 10.5 | HSP | sCr 2.26 mg/dL (200 µmol/L) | 80% crescents | 9 months from onset | Steroids Cytoxan | sCr 2.26 mg/dL (200 µmol/L) 2 months after PLEX ESKD at 1-year follow up | - | |||
| 13 | M | 8.5 | HSP | sCr 5.32 mg/dL (470 µmol/L) | 100% crescents | 2 months from onset | Steroids Cytoxan HD | sCr 2.04 mg/dL (180 µmol/L) 2 months after PLEX ESKD at 1-year follow up | - | |||
| 14 | M | 6.7 | HSP | sCr 2.6 mg/dL (230 µmol/L) | 85% crescents | 2 months from onset | Steroids Cytoxan | sCr 0.96 mg/dL (85 µmol/L) 2 months after PLEX 0.97 mg/dL (86 µmol/L) at 9-year follow up | - | |||
| 5 | Shenoy [54] | 2007 | UK | 16 (14 with HSP and 2 IgAN) pts; 6M and 10F | 3.7–13.5 | HSP IgAN | eGFR estimated using sCr and height | All patients with at least grade 3 nephritis on biopsy were treated with plasmapheresis alone. Plasmapheresis 90 mL/kg per session exchanging 80 mL/kg with 4.5% albumin and 20 mL/kg with FFP. All patients received at least 9 sessions in first 2 weeks with further increasing spaced sessions if clinical recovery was incomplete. All patients received cotrimoxazole 12 mg/kg daily for duration of treatment plus 2 months. | None | All patients had improvement in eGFR and UA/UC ratio that was stable over time, but the delayed patient ultimately required kidney transplant. Results suggest prompt treatment with plasmapheresis alone improves kidney function that remains stable over time. | Itchy rashes following FFP treated with hydrocortisone and chlorphenamine | |
| 1 | F | 11.0 | HSP | eGFR 46 | ISKDC grade 3b 20% crescents | Within 2 weeks of onset | None | eGFR 102 with negative urine dipstick for albumin at 7.5 years follow up | - | |||
| 2 | F | 6.8 | HSP | eGFR 82 | ISKDC grade 3a 40% crescents | Within 2 weeks of onset | None | eGFR 127 and UA/UC 2 at 1.1 year follow up | - | |||
| 3 | M | 5.8 | HSP | eGFR 93 | ISKDC grade 3b 24% crescents | Within 2 weeks of onset | None | eGFR 98 and UA/UC 3 at 2.1 years follow up | - | |||
| 4 | M | 15.0 | HSP | eGFR 20 | ISKDC grade 3b 20% crescents | Within 2 weeks of onset | None | eGFR 108 and UA/UC 38 at 2.5 years follow up | - | |||
| 5 | F | 3.7 | HSP | eGFR 136 | ISKDC grade 3a No crescents | Within 2 weeks of onset | None | eGFR 102 and UA/UC 2 at 6.2 years follow up | - | |||
| 6 | F | 13.5 | HSP | eGFR 28 | ISKDC grade 4b 53% crescents | Within 2 weeks of onset | None | eGFR 134 and UA/UC 42 at 2.6 years follow up | - | |||
| 7 | F | 12.5 | HSP | eGFR 61 | ISKDC grade 3b 43% crescents | Within 2 weeks of onset | None | eGFR 101 and UA/UC 10 at 3.1 years follow up | - | |||
| 8 | M | 11.8 | HSP | eGFR 33 | ISKDC grade 3b no crescents | Within 2 weeks of onset | None | eGFR 142 and UA/UC 1 at 3.8 years follow up | - | |||
| 9 | M | 12.3 | HSP | eGFR 90 | ISKDC grade 3b 10% crescents | Within 2 weeks of onset | None | eGFR 101 and UA/UC 7 at 1.1 years follow up | - | |||
| 10 | F | 10.1 | IgAN | eGFR 42 | ISKDC grade 3b 29% fibrous crescents | Within 2 weeks of onset | None | eGFR 106 and UA/UC 2 at 4.2 years follow up | - | |||
| 11 | M | 13.1 | IgAN | eGFR 17 | ISKDC grade 3b 5% crescents | Within 2 weeks of onset | None | eGFR 113 and UA/UC 16 at 3.4 years follow up | - | |||
| 12 | M | 9.9 | HSP | eGFR 43 | ISKDC grade 3b 14% fibrous crescents | Within 2 weeks of onset | None | eGFR 105 and UA/UC 9 at 5.2 years follow up | - | |||
| 13 | F | 8.4 | HSP | eGFR 64 | ISKDC grade 4b 52% crescents | Within 2 weeks of onset | None | eGFR 121 and UA/UC 14.3 at 5.5 years follow up | - | |||
| 14 | F | 8.3 | HSP | eGFR 22 | ISKDC grade 3a no crescents | Within 2 weeks of onset | None | eGFR 121 and UA/UC 2 at 4.3 years follow up | - | |||
| 15 | F | 8.9 | HSP | eGFR 67 | ISKDC grade 3b no crescents | Within 2 weeks of onset | None | eGFR 112 and UA/UC 3 at 5.4 years follow up | - | |||
| 16 | F | 7.7 | HSP | eGFR 29 | ISKDC grade 3b 26% fibrous crescents | Plasma exchange delayed until 2 months from onset due to needle phobia. | None | Kidney Transplant at 6.3 years follow up | - | |||
| 6 | Wright [55] | 2006 | UK | 32 pts; 5 with HSP, gender and specific ages not specified. | Median 9.4 (0.7–17.7 years) | 5 with HSP, Rest had collection of PAN, GPA, MPA/ICN, and NCV | eGFR obtained using Schwartz formula | All patients received at least 2 courses of plasma exchange comprised of 5 daily sessions and extra sessions based on clinical response. TPE performed using Spectra centrifugation and PF 1000 plasma filter and Gambro AK 10. Plasma volume was calculated as 50 mL/kg bodyweight with target of double volume as target with limit of 4 L. Plasma replaced with 4.5% albumin in all cases, with FFP at the end of exchange to replenish clotting factors. Median time to treatment from admission was 6 days (range 0–28 days). | Steroids Cytoxan | Hypotension Femoral vein thrombosis Sepsis | ||
| 1 | Gender not specified | -- | HSP | eGFR 64 | 48% crescents pre-TPE | Did not specify specific time/number of sessions. | Steroids Cytoxan | eGFR 106 after plasma exchange eGFR 162 at 2 months follow up | - | |||
| 2 | Gender not specified | -- | HSP | eGFR 22 | 100% crescents pre-TPE | Did not specify specific time/number of sessions. | Steroids Cytoxan | eGFR 26 after plasma exchange eGFR 66 at 2 months follow up Required HD temporarily but gradually regained kidney function | - | |||
| 3 | Gender not specified | -- | HSP | eGFR 33 | 100% crescents pre-TPE | Did not specify specific time/number of sessions. | Steroids Cytoxan | eGFR 20 after plasma exchange eGFR 10 at 2 months follow up Required HD 2 months after plasma exchange | - | |||
| 4 | Gender not specified | -- | HSP | eGFR 167 | 50% crescents pre-TPE | Did not specify specific time/number of sessions. | Steroids Cytoxan | eGFR 177 after plasma exchange eGFR 169 at 2 months follow up | - | |||
| 5 | Gender not specified | -- | HSP | eGFR 84 | 75% crescents pre-TPE | Did not specify specific time/number of sessions. | Steroids Cytoxan | eGFR 98 after plasma exchange eGFR 99 at 2 months follow up | - | |||
| 7 | Xie [56] | 2016 | China | 12 patients; 9M and 3F. No individual data available. | Mean 42.7± SD 15 | 8 patients on HD at start 2 patients with oliguria 11 patients with HTN | Mean sCr 7.98 ± 3.35 mg/dL (705.3 ± 296.4 μmol/L) | Total glomeruli 21 64.4 ± 24.4% crescents; 6 patients 50%< tubular atrophy | Mean 7 sessions (5–10) over mean of 15 days (9–30). 2.517 L exchanged per course (300) Median time of symptoms was 1.5 months (1.0–5.0). | Steroids Cytoxan Some with Mycophenolate | Compared to matched historical control group, about half of plasma exchange group were able to discontinue dialysis in 6 months. 5 patients with significant reduction in sCr to normal range that was stable in long-term follow-up (9 to 51 months). 7 patients with ESKD | Pneumonia Pulmonary Failure |
| 8 | Chambers [57] | 1999 | USA | 2 patients | ||||||||
| M | 27 | IgAN | 2.8 mg/dL (247.58 μmol/L); proteinuria 6.2 g/day | Crescentic GN | 6 × 4 L exchanges over 18 days initiated during pt’s readmission. | Steroids, Cytoxan | sCr 5.6 and proteinuria 3.5 g/day, no response to PLEX. ESKD | none | ||||
| M | 18 | IgAN | 23 mg/dL (2033.66 μmol/L); >5 g/day | Crescentic GN | 7 × 4 L exchanges over 18 days. | Steroids, Cytoxan | ESKD | Sepsis from catheter | ||||
| 9 | Rajgopala [58] | 2017 | India | 2 patients | ||||||||
| 1 | F | 38 | DAH | sCr 7.8 mg/dL (689.68 umol/L) | Crescentic GN | Did not specify regimen. | Steroid, Cytoxan | Stable on HD and DAH improved but expired from ventricular arrhythmia during HD on admission day 18 | Expired | |||
| 2 | M | 45 | DAH | sCr 5.3 mg/dL (689.68 umol/L) | Crescentic GN | Did not specify regimen. | Steroid, Cytoxan, ECMO | DAH not improved; expired from septic shock | Septic shock, Expired |
Abbreviations: AZA, Azathioprine; DAH, diffuse alveolar hemorrhage; ECMO, extracorporeal membrane oxygenation; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; GN, glomerulonephritis; GPA, granulomatosis with polyangiitis; HSP, Henoch-Schönlein purpura; HTN, hypertension; ICN, idiopathic crescentic nephritis; IgAN, IgA nephropathy with Crescentic glomerular involvement; ISKDC, International Study of Kidney Disease in Children; MPA, microscopic polyangiitis; NCV, non-specified vasculitis; PAN, polyarteritis nodosa; PLEX, plasma exchange therapy; sCr, serum creatinine; TPE, therapeutic plasma exchange.
Table 3.
Reported adverse events.
| Adverse Events | Number of Patients |
|---|---|
| Infectious complication | 8 (7.8%) |
| Mild allergic reaction | 1 (0.98%) |
| Electrolyte abnormality (hypocalcemia) | 1 (0.98%) |
| Catheter dislodgement | 1 (0.98%) |
| Volume overload | 1 (0.98%) |
| Vein thrombosis | 1 (0.98%) |
| Anaphylaxis | 1 (0.98%) |
| Leukopenia | 1 (0.98%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Nguyen, B.; Acharya, C.; Tangpanithandee, S.; Miao, J.; Krisanapan, P.; Thongprayoon, C.; Amir, O.; Mao, M.A.; Cheungpasitporn, W.; Acharya, P.C. Efficacy and Safety of Plasma Exchange as an Adjunctive Therapy for Rapidly Progressive IgA Nephropathy and Henoch-Schönlein Purpura Nephritis: A Systematic Review. Int. J. Mol. Sci. 2023, 24, 3977. https://doi.org/10.3390/ijms24043977
AMA Style
Nguyen B, Acharya C, Tangpanithandee S, Miao J, Krisanapan P, Thongprayoon C, Amir O, Mao MA, Cheungpasitporn W, Acharya PC. Efficacy and Safety of Plasma Exchange as an Adjunctive Therapy for Rapidly Progressive IgA Nephropathy and Henoch-Schönlein Purpura Nephritis: A Systematic Review. International Journal of Molecular Sciences. 2023; 24(4):3977. https://doi.org/10.3390/ijms24043977
Chicago/Turabian StyleNguyen, Bryan, Chirag Acharya, Supawit Tangpanithandee, Jing Miao, Pajaree Krisanapan, Charat Thongprayoon, Omar Amir, Michael A. Mao, Wisit Cheungpasitporn, and Prakrati C. Acharya. 2023. "Efficacy and Safety of Plasma Exchange as an Adjunctive Therapy for Rapidly Progressive IgA Nephropathy and Henoch-Schönlein Purpura Nephritis: A Systematic Review" International Journal of Molecular Sciences 24, no. 4: 3977. https://doi.org/10.3390/ijms24043977
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
